Comparison of Duloxetine Supplemented With Pregabalin and Amitriptyline Supplemented With Pregabalin for the Treatment of Postherpetic Neuralgia: A Double‐Blind, Randomized Crossover Trial
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70460 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Yue Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Amitriptyline, Neuralgia, Postherpetic, Analgesics, gamma-Aminobutyric Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanjing Drum Tower Hospital integrated traditional Chinese and Western medicine characteristic technology development project, Medical Science and Technology Development Project of Nanjing, Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University.
Abstract (Originalsprache)
Background
Postherpetic neuralgia (PHN) is the most common chronic complication of herpes zoster (HZ), and current treatment regimens often fail to effectively control the pain.
Aim
The purpose of this study is to compare the efficacy and tolerability of duloxetine combined with pregabalin and amitriptyline combined with pregabalin in the treatment of PHN, as well as their impact on sleep and quality of life in patients with PHN.
Methods
This is a double‐blind, randomized, crossover trial involving PHN patients. About 220 participants were randomly assigned (1:1) to either the duloxetine combined with pregabalin or the amitriptyline combined with pregabalin. The patient takes duloxetine or amitriptyline orally before bedtime for 6 weeks each time. Perform a 2‐week single‐blind placebo washout between the two treatments, and a 2‐week single‐blind placebo washout at the end of the treatment period. In the last week of the treatment cycle, evaluate the 7‐day average daily pain, Pittsburgh Sleep Quality Index, 17‐item Hamilton Depression Rating Scale, 36‐Item Short Form Health Survey, and record the occurrence of major adverse events. A median reduction of 50%, 25%–50%, and 25% in pain score is considered good, moderate, and mild improvement, respectively.
Results
Both treatment methods can significantly improve the baseline pain value ( p < 0.001 for both). The combination of duloxetine and pregabalin resulted in good, moderate, and mild pain relief of 52%, 24%, and 7%, respectively. The combination of amitriptyline and pregabalin resulted in good, moderate, and mild pain relief of 48%, 21%, and 9%, respectively. There was no significant difference in the measurement of various results between the two groups. In the reported adverse events, patients in the amitriptyline group had significantly more dry mouth compared to the duloxetine group (26% vs. 11%; p = 0.008).
Conclusions
Duloxetine and amitriptyline have similar analgesic effects, and the difference is not statistically significant. The combination of pregabalin has good tolerability and better pain relief in PHN patients, thus providing clinically relevant benefits. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2100054831
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pain, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Pain, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
ORCID-Profile: Ying Huang
Förderung
- Nanjing Drum Tower Hospital integrated traditional Chinese and Western medicine characteristic technology development project
- Medical Science and Technology Development Project of Nanjing
- Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
Zitieren
APA
Wang, Y., Wu, C., Liu, Y., Lou, Y., Chen, C., Chen, Q., Li, X., Ma, C., Li, J., & Huang, Y. (2025). Comparison of Duloxetine Supplemented With Pregabalin and Amitriptyline Supplemented With Pregabalin for the Treatment of Postherpetic Neuralgia: A Double‐Blind, Randomized Crossover Trial. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70460
Vancouver
Wang Y, Wu C, Liu Y, Lou Y, Chen C, Chen Q, et al. Comparison of Duloxetine Supplemented With Pregabalin and Amitriptyline Supplemented With Pregabalin for the Treatment of Postherpetic Neuralgia: A Double‐Blind, Randomized Crossover Trial. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70460
BibTeX
@article{Wang2025,
author = {Wang, Yue and Wu, Chenchen and Liu, Yanan and Lou, Youpan and Chen, Cheng and Chen, Qianqian and Li, Xihan and Ma, Chao and Li, Jing and Huang, Ying},
title = {Comparison of Duloxetine Supplemented With Pregabalin and Amitriptyline Supplemented With Pregabalin for the Treatment of Postherpetic Neuralgia: A Double‐Blind, Randomized Crossover Trial},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70460}
}
EUVIMED